Cargando…
Safety and Efficacy of Fremanezumab for the Prevention of Migraine: A Meta-Analysis From Randomized Controlled Trials
Background: Fremanezumab (TEV-48125) is a fully-humanized immunoglobulin G isotype 2a selective monoclonal antibody that potently binds to calcitonin gene-related peptide (CGRP). It is one of the novel therapeutic drugs for the prevention of migraine, which is one of the most common neurological dis...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7248404/ https://www.ncbi.nlm.nih.gov/pubmed/32508742 http://dx.doi.org/10.3389/fneur.2020.00435 |
_version_ | 1783538365803528192 |
---|---|
author | Gao, Bixi Sun, Nan Yang, Yanbo Sun, Yue Chen, Mingjia Chen, Zhouqing Wang, Zhong |
author_facet | Gao, Bixi Sun, Nan Yang, Yanbo Sun, Yue Chen, Mingjia Chen, Zhouqing Wang, Zhong |
author_sort | Gao, Bixi |
collection | PubMed |
description | Background: Fremanezumab (TEV-48125) is a fully-humanized immunoglobulin G isotype 2a selective monoclonal antibody that potently binds to calcitonin gene-related peptide (CGRP). It is one of the novel therapeutic drugs for the prevention of migraine, which is one of the most common neurological diseases worldwide. Several controlled trials have been conducted to investigate the safety and efficacy of fremanezumab, however, there is no systematic review of the existing literature has been performed. Hence, in our study, we performed a meta-analysis to investigate the safety and efficacy of fremanezumab for the prevention of migraine. Method: Pubmed (MEDLINE), Embase, and Cochrane Library were searched from January 2001 to August 2019 for randomized controlled trials (RCTs). Five RCTs with 3,379 patients were finally included in our study. Result: We pooled 3,379 patients from 5 RCTs; the primary endpoints were mean monthly migraine and headache days, baseline to week 12. We found that fremanezumab led to a significant reduction in migraine days (P < 0.0001) and headache days (P < 0.0001) during 12 weeks compared with placebo. Moreover, after using fremanezumab, the risk of at least one adverse event (AE) (P = 0.001) and AE related to the trial regimen (P = 0.0005) significantly increased compared with the placebo. Conclusions: Fremanezumab showed good efficacy for the prevention of migraine. The administration of fremanezumab can cause some mild adverse events but no serious adverse events. |
format | Online Article Text |
id | pubmed-7248404 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-72484042020-06-05 Safety and Efficacy of Fremanezumab for the Prevention of Migraine: A Meta-Analysis From Randomized Controlled Trials Gao, Bixi Sun, Nan Yang, Yanbo Sun, Yue Chen, Mingjia Chen, Zhouqing Wang, Zhong Front Neurol Neurology Background: Fremanezumab (TEV-48125) is a fully-humanized immunoglobulin G isotype 2a selective monoclonal antibody that potently binds to calcitonin gene-related peptide (CGRP). It is one of the novel therapeutic drugs for the prevention of migraine, which is one of the most common neurological diseases worldwide. Several controlled trials have been conducted to investigate the safety and efficacy of fremanezumab, however, there is no systematic review of the existing literature has been performed. Hence, in our study, we performed a meta-analysis to investigate the safety and efficacy of fremanezumab for the prevention of migraine. Method: Pubmed (MEDLINE), Embase, and Cochrane Library were searched from January 2001 to August 2019 for randomized controlled trials (RCTs). Five RCTs with 3,379 patients were finally included in our study. Result: We pooled 3,379 patients from 5 RCTs; the primary endpoints were mean monthly migraine and headache days, baseline to week 12. We found that fremanezumab led to a significant reduction in migraine days (P < 0.0001) and headache days (P < 0.0001) during 12 weeks compared with placebo. Moreover, after using fremanezumab, the risk of at least one adverse event (AE) (P = 0.001) and AE related to the trial regimen (P = 0.0005) significantly increased compared with the placebo. Conclusions: Fremanezumab showed good efficacy for the prevention of migraine. The administration of fremanezumab can cause some mild adverse events but no serious adverse events. Frontiers Media S.A. 2020-05-19 /pmc/articles/PMC7248404/ /pubmed/32508742 http://dx.doi.org/10.3389/fneur.2020.00435 Text en Copyright © 2020 Gao, Sun, Yang, Sun, Chen, Chen and Wang. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Neurology Gao, Bixi Sun, Nan Yang, Yanbo Sun, Yue Chen, Mingjia Chen, Zhouqing Wang, Zhong Safety and Efficacy of Fremanezumab for the Prevention of Migraine: A Meta-Analysis From Randomized Controlled Trials |
title | Safety and Efficacy of Fremanezumab for the Prevention of Migraine: A Meta-Analysis From Randomized Controlled Trials |
title_full | Safety and Efficacy of Fremanezumab for the Prevention of Migraine: A Meta-Analysis From Randomized Controlled Trials |
title_fullStr | Safety and Efficacy of Fremanezumab for the Prevention of Migraine: A Meta-Analysis From Randomized Controlled Trials |
title_full_unstemmed | Safety and Efficacy of Fremanezumab for the Prevention of Migraine: A Meta-Analysis From Randomized Controlled Trials |
title_short | Safety and Efficacy of Fremanezumab for the Prevention of Migraine: A Meta-Analysis From Randomized Controlled Trials |
title_sort | safety and efficacy of fremanezumab for the prevention of migraine: a meta-analysis from randomized controlled trials |
topic | Neurology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7248404/ https://www.ncbi.nlm.nih.gov/pubmed/32508742 http://dx.doi.org/10.3389/fneur.2020.00435 |
work_keys_str_mv | AT gaobixi safetyandefficacyoffremanezumabforthepreventionofmigraineametaanalysisfromrandomizedcontrolledtrials AT sunnan safetyandefficacyoffremanezumabforthepreventionofmigraineametaanalysisfromrandomizedcontrolledtrials AT yangyanbo safetyandefficacyoffremanezumabforthepreventionofmigraineametaanalysisfromrandomizedcontrolledtrials AT sunyue safetyandefficacyoffremanezumabforthepreventionofmigraineametaanalysisfromrandomizedcontrolledtrials AT chenmingjia safetyandefficacyoffremanezumabforthepreventionofmigraineametaanalysisfromrandomizedcontrolledtrials AT chenzhouqing safetyandefficacyoffremanezumabforthepreventionofmigraineametaanalysisfromrandomizedcontrolledtrials AT wangzhong safetyandefficacyoffremanezumabforthepreventionofmigraineametaanalysisfromrandomizedcontrolledtrials |